Corvus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Corvus Pharmaceuticals

19/03/2024 21:01

* Corvus Pharmaceuticals Inc  CRVS.OQ  reported a quarterly
adjusted loss of 14 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -21 cents.  The mean expectation of
four analysts for the quarter was for a loss of 12 cents per
share. Wall Street expected results to range from -13 cents
to -10 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Corvus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 14 cents​.
    * The company reported a quarterly loss of $6.65 million.
    * Corvus Pharmaceuticals Inc shares had risen by 8.0% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Corvus
Pharmaceuticals Inc is $8.00 

This summary was machine generated from LSEG data March 19 at
09:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.12          -0.14          Missed
 Sep. 30 2023      -0.12          -0.12          Met
 Jun. 30 2023      -0.14          -0.14          Met
 Mar. 31 2023      -0.16          -0.17          Missed